<?xml version='1.0' encoding='utf-8'?>
<document id="29569723"><sentence text="Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin."><entity charOffset="130-138" id="DDI-PubMed.29569723.s1.e0" text="Rifampin" /></sentence><sentence text="Drug transporter and cytochrome P450 expression is regulated by shared nuclear receptors and, hence, an inducer should induce both, although the magnitude may differ" /><sentence text=" The objective of this study was to establish relative induction relationships between CYP3A and drug transporters (P-glycoprotein (P-gp), organic anion transporting polypeptide (OATP), and breast cancer resistance protein (BCRP)) or other P450s (CYP2C9 and CYP1A2) using ascending doses of the prototypical pregnane xenobiotic receptor (PXR) agonist, rifampin, to elicit weak, moderate, and strong PXR agonism"><entity charOffset="352-360" id="DDI-PubMed.29569723.s3.e0" text="rifampin" /></sentence><sentence text=" Healthy subjects received dabigatran etexilate, pravastatin, rosuvastatin, and a midazolam/tolbutamide/caffeine cocktail before and after rifampin 2, 10, 75, or 600â€‰mg q"><entity charOffset="27-47" id="DDI-PubMed.29569723.s4.e0" text="dabigatran etexilate" /><entity charOffset="49-60" id="DDI-PubMed.29569723.s4.e1" text="pravastatin" /><entity charOffset="62-74" id="DDI-PubMed.29569723.s4.e2" text="rosuvastatin" /><entity charOffset="82-91" id="DDI-PubMed.29569723.s4.e3" text="midazolam" /><entity charOffset="92-103" id="DDI-PubMed.29569723.s4.e4" text="tolbutamide" /><entity charOffset="104-112" id="DDI-PubMed.29569723.s4.e5" text="caffeine" /><entity charOffset="139-147" id="DDI-PubMed.29569723.s4.e6" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e0" e2="DDI-PubMed.29569723.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e0" e2="DDI-PubMed.29569723.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e0" e2="DDI-PubMed.29569723.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e0" e2="DDI-PubMed.29569723.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e0" e2="DDI-PubMed.29569723.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e0" e2="DDI-PubMed.29569723.s4.e5" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e0" e2="DDI-PubMed.29569723.s4.e6" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e1" e2="DDI-PubMed.29569723.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e1" e2="DDI-PubMed.29569723.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e1" e2="DDI-PubMed.29569723.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e1" e2="DDI-PubMed.29569723.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e1" e2="DDI-PubMed.29569723.s4.e5" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e1" e2="DDI-PubMed.29569723.s4.e6" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e2" e2="DDI-PubMed.29569723.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e2" e2="DDI-PubMed.29569723.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e2" e2="DDI-PubMed.29569723.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e2" e2="DDI-PubMed.29569723.s4.e5" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e2" e2="DDI-PubMed.29569723.s4.e6" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e3" e2="DDI-PubMed.29569723.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e3" e2="DDI-PubMed.29569723.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e3" e2="DDI-PubMed.29569723.s4.e5" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e3" e2="DDI-PubMed.29569723.s4.e6" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e4" e2="DDI-PubMed.29569723.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e4" e2="DDI-PubMed.29569723.s4.e5" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e4" e2="DDI-PubMed.29569723.s4.e6" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e5" e2="DDI-PubMed.29569723.s4.e5" /><pair ddi="false" e1="DDI-PubMed.29569723.s4.e5" e2="DDI-PubMed.29569723.s4.e6" /></sentence><sentence text="d" /><sentence text=" Unlike CYP3A, only moderate induction of P-gp, OATP, and CYP2C9 was observed and dose-dependent induction of P-gp, OATP, and CYP2C9 was always one drug-drug interaction category lower than observed for CYP3A, even when correcting for probe drug sensitivity" /><sentence text=" Data from this study establish proof-of-concept that P450 induction data can be leveraged to inform on the effect on transporters" /><sentence text="" /></document>